Sen. Brown Urges Pharmaceutical Company to Halt Massive Increase for Critical Preterm Labor Drug

Sen. Brown Urges Pharmaceutical Company to Halt Massive Increase for Critical Preterm Labor Drug
Pharmaceutical Company Plans to Raise Price from $10 to $1,500 per Dose
March 10, 2011


WASHINGTON, D.C. - Following reports of a price increases on a drug to prevent preterm pregnancy, U.S. Sen. Sherrod Brown (D-OH) today urged KV Pharmaceutical Company to reverse course. In a letter to KV Pharmaceutical Company's CEO, Brown called on the company to maintain access of the critical drug and stem an increase in premature births.

"It's critical to ensure that American drugs are safe, but I become deeply concerned when it appears that a drug company may be taking advantage of FDA approval at the expense of women, children, and federal and state budgets," Brown said. "By ratcheting up prices, fewer women will be able to afford the drug, increasing rates of preterm birth nationwide. This isn't in the interest of children, new mothers, or taxpayers."

The drug for high-risk pregnant women, which KV Pharmacutical plans to sell under the brand name Makena, has been produced by compounding pharmacies for years and typically costs between $10-20. Last month, KV Pharmaceutical became the first company to receive FDA approval to sell the product and plans to raise the cost to $1,500 per dosage. Brown noted this price increase could lead to fewer women being able to afford the drug, increasing our nation's already too-high preterm birth rate of 13 percent. Higher costs mean that health insurance companies could either stop coverage of the treatment or impose higher premiums on consumers and already stretched state Medicaid programs would be forced to deal with the financial repercussions of the company's decision.
Below is the full text of the letter.

March 10, 2011

Greg Divis
Chief Executive Officer
KV Pharmaceutical Company
President
Ther-Rx Corporation
One Corporate Woods Drive
Bridgeton, MO 63044

Dear Mr. Divis:

According to reports in the Associated Press, your company plans to impose a massive price increase on a drug that, for years, has worked to prevent preterm labor in high-risk pregnant women.  Not only will this price hike be overly burdensome on state Medicaid programs and health insurance companies, it will invariably result in reduced access and, as a result, more premature births.

For years, this progesterone treatment, which you plan to sell under the brand name Makena, has been produced by compounding pharmacies.  Last month, KV Pharmaceutical became the first company to receive FDA approval to sell this product.  While I understand and commend the Food and Drug Administration (FDA) for their efforts to ensure that drugs marketed and sold in the United States are safe and effective, I am deeply concerned that your company appears to be taking advantage of FDA approval at the expense of women, children, and federal and state budgets. 

Prior to your company receiving FDA approval, this important drug had been available to women at a cost of $10-20 per injection.  Reports indicate that, next week, you plan to raise the price to $1,500 per shot.  This represents an increase of up to 14,900 percent.  The drug industry attributes the high price tag of the brand name medicines it sells in the United States to the cost of research and development (R&D).  Since it is likely that the only material R&D costs your company incurred in order to receive approval of this drug were those associated with conducting clinical trials, it is disturbing that you have chosen to inflate its price so dramatically.

According to the March of Dimes, nearly 13 percent of babies in the United States are born prematurely - more than half a million a year.  In yet another example of unacceptable health disparities in our nation, non-Hispanic black women have a higher proportion of preterm births than Hispanics and non-Hispanic whites.  Babies born prematurely face increased risks of lung problems, hearing and vision loss, cerebral palsy, and other learning and behavioral health problems.  In addition to the health concerns related to preterm births, the financial cost to our nation is significant.  For instance, Nationwide Children's Hospital reports that Neonatal Intensive Care Unit (NICU) stays average $66,000 in Franklin County, Ohio and can cost in excess of $2 million.  In 2006, the Institute of Medicine found that preterm births cost the United States at least $26 billion annually.

I am gravely concerned that the exorbitant price increase your company plans to implement next week will increase rates of preterm birth nationwide.  Fewer women will be able to afford the drug, health insurance companies could either stop coverage of the treatment or impose higher premiums on consumers, and state Medicaid programs - which are already struggling to make ends meet - will be forced to deal with the financial repercussions of your company's decision.
I ask that you immediately reconsider this massive price increase.
Sincerely,

Sherrod Brown
United States Senator

###

 

--------------------------------------------------------------------------------

Press Contacts:

202-224-3978


--------------------------------------------------------------------------------

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.